<?xml version="1.0" encoding="UTF-8"?>
<fig id="fig5" position="float" orientation="portrait">
 <object-id pub-id-type="doi">10.7554/eLife.42496.010</object-id>
 <label>Figure 5.</label>
 <caption>
  <title>Antigenic novelty predicts serotype success.</title>
  <p>(
   <bold>A</bold>) The relative frequency of each serotype, 
   <inline-formula>
    <math id="inf46">
     <msub>
      <mi>x</mi>
      <mi>i</mi>
     </msub>
    </math>
   </inline-formula>, in Southeast Asia estimated every 3 months based on available sequence data. (
   <bold>B</bold>) Total fitness of each serotype. We calculate antigenic fitness for each serotype over time as its frequency-weighted antigenic distance from recently circulating viruses. We then add this to a time-invariant intrinsic fitness value to calculate total fitness. (
   <bold>C</bold>) DENV1 frequencies between 1994 and 1996 alongside model projection. At each timepoint 
   <inline-formula>
    <math id="inf47">
     <mi>t</mi>
    </math>
   </inline-formula>, we blind the model to all empirical data from timepoints later than 
   <inline-formula>
    <math id="inf48">
     <mi>t</mi>
    </math>
   </inline-formula> and predict each serotype’s future trajectory based on its initial frequency, time-invariant intrinsic fitness, and antigenic fitness at time 
   <inline-formula>
    <math id="inf49">
     <mi>t</mi>
    </math>
   </inline-formula> (Materials and methods, 
   <xref ref-type="disp-formula" rid="equ11">Equation 11</xref>). We predict forward in 3-month increments for a total prediction period of 
   <inline-formula>
    <math id="inf50">
     <mrow>
      <mrow>
       <mi>d</mi>
       <mo>⁢</mo>
       <mi>t</mi>
      </mrow>
      <mo>=</mo>
      <mn>2</mn>
     </mrow>
    </math>
   </inline-formula> years. At each increment, we use the current predicted frequency to adjust our estimates of antigenic fitness on a rolling basis (Materials and methods, 
   <xref ref-type="disp-formula" rid="equ16">Equation 15</xref>). (
   <bold>D</bold>) Predicted growth rates, 
   <inline-formula>
    <math id="inf51">
     <mrow>
      <mover accent="true">
       <mi>g</mi>
       <mo stretchy="false">^</mo>
      </mover>
      <mo>=</mo>
      <mfrac>
       <mrow>
        <mover accent="true">
         <msub>
          <mi>x</mi>
          <mi>i</mi>
         </msub>
         <mo stretchy="false">^</mo>
        </mover>
        <mo>⁢</mo>
        <mrow>
         <mo stretchy="false">(</mo>
         <mrow>
          <mi>t</mi>
          <mo>+</mo>
          <mrow>
           <mi>d</mi>
           <mo>⁢</mo>
           <mi>t</mi>
          </mrow>
         </mrow>
         <mo stretchy="false">)</mo>
        </mrow>
       </mrow>
       <mrow>
        <msub>
         <mi>x</mi>
         <mi>i</mi>
        </msub>
        <mo>⁢</mo>
        <mrow>
         <mo stretchy="false">(</mo>
         <mi>t</mi>
         <mo stretchy="false">)</mo>
        </mrow>
       </mrow>
      </mfrac>
     </mrow>
    </math>
   </inline-formula>, compared to empirically observed growth rates, 
   <inline-formula>
    <math id="inf52">
     <mrow>
      <mi>g</mi>
      <mo>=</mo>
      <mfrac>
       <mrow>
        <msub>
         <mi>x</mi>
         <mi>i</mi>
        </msub>
        <mo>⁢</mo>
        <mrow>
         <mo stretchy="false">(</mo>
         <mrow>
          <mi>t</mi>
          <mo>+</mo>
          <mrow>
           <mi>d</mi>
           <mo>⁢</mo>
           <mi>t</mi>
          </mrow>
         </mrow>
         <mo stretchy="false">)</mo>
        </mrow>
       </mrow>
       <mrow>
        <msub>
         <mi>x</mi>
         <mi>i</mi>
        </msub>
        <mo>⁢</mo>
        <mrow>
         <mo stretchy="false">(</mo>
         <mi>t</mi>
         <mo stretchy="false">)</mo>
        </mrow>
       </mrow>
      </mfrac>
     </mrow>
    </math>
   </inline-formula>. Predicted and empirical growth rate of the example illustrated in (
   <bold>C</bold>) is shown in (
   <bold>D</bold>) as the blue point. Serotype growth versus decline is accurate (i.e. the predicted and actual growth rates are both 
   <inline-formula>
    <math id="inf53">
     <mrow>
      <mi/>
      <mo>&gt;</mo>
      <mn>1</mn>
     </mrow>
    </math>
   </inline-formula> or both 
   <inline-formula>
    <math id="inf54">
     <mrow>
      <mi/>
      <mo>&lt;</mo>
      <mn>1</mn>
     </mrow>
    </math>
   </inline-formula>, all points outside the gray area) for 66% of predictions.
  </p>
 </caption>
 <graphic xlink:href="elife-42496-fig5" xmlns:xlink="http://www.w3.org/1999/xlink"/>
 <p content-type="supplemental-figure">
  <fig id="fig5s1" specific-use="child-fig" orientation="portrait" position="anchor">
   <object-id pub-id-type="doi">10.7554/eLife.42496.011</object-id>
   <label>Figure 5—figure supplement 1.</label>
   <caption>
    <title>Case counts versus clade frequencies in Thailand.</title>
    <p>As described in the Materials and methods, we estimate clade frequencies based on observed relative abundance in the ‘slice’ of the phylogeny at each quarterly timepoint. These frequency estimates are smoothed using a discretized Brownian motion diffusion process. Here, we compare estimated serotype frequencies across Thailand (all available high quality sequences) to case counts from a hospital in Bangkok between 1975–2010 (
     <xref rid="bib41" ref-type="bibr">Reich et al., 2013</xref>). Biweekly case counts were aggregated into quarterly timepoints, but were not smoothed. While there are some instances where case counts and frequencies diverge (e.g. DENV4 in the early 1990s), the noisy nature of the unsmoothed case counts artificially deflates estimates of concordance.
    </p>
   </caption>
   <graphic xlink:href="elife-42496-fig5-figsupp1" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </fig>
 </p>
 <p content-type="supplemental-figure">
  <fig id="fig5s2" specific-use="child-fig" orientation="portrait" position="anchor">
   <object-id pub-id-type="doi">10.7554/eLife.42496.013</object-id>
   <label>Figure 5—figure supplement 2.</label>
   <caption>
    <title>Simulated serotype frequencies (model parameters).</title>
    <p>As described in the Materials and methods, we seeded a simulation with two years of empirical frequencies and predicted forward to simulate the remainder of the timecourse. Here, we simulated under the model parameters described in 
     <xref rid="table2" ref-type="table">Table 2</xref>. This results in damped oscillations around the intrinsic fitness value for each serotype, but these intrinsic fitnesses alone are unable to predict observed clade dynamics (
     <xref rid="table3" ref-type="table">Table 3</xref>).
    </p>
   </caption>
   <graphic xlink:href="elife-42496-fig5-figsupp2" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </fig>
 </p>
 <p content-type="supplemental-figure">
  <fig id="fig5s3" specific-use="child-fig" orientation="portrait" position="anchor">
   <object-id pub-id-type="doi">10.7554/eLife.42496.012</object-id>
   <label>Figure 5—figure supplement 3.</label>
   <caption>
    <title>Simulated serotype frequencies.</title>
    <p>As described in the Materials and methods, we seeded a simulation with 2 years of empirical frequencies and predicted forward to simulate the remainder of the timecourse. Here, we simulated under the model parameters described in 
     <xref rid="table5" ref-type="table">Table 5</xref>.
    </p>
   </caption>
   <graphic xlink:href="elife-42496-fig5-figsupp3" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  </fig>
 </p>
</fig>
